الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
This is a case-control study aimed at searching for the presence of factor V leiden and prothrombin G20210A mutation in patient with congenital acyanotic heart disease for early detection and management for patients who are at risk for thrombosis. Conclusion:-The risk of thrombosis development in CHD patients is multifactorial and mostly are related to environmental risk factors. In children with acyanotic CHD,certain coagulation and anticoagulation factors have been shown to be decreased in an age dependent manner, making them similar to those measured in cyanotic CHD e.g; at age 0 to 3 months: decreased levels of protein C, ant thrombin III, FII, FV, FVII, FVIII, FIX, FX, and plasminogen, at age 3 to 12 months: decreased levels of protein c, anti thrombin , FII, FV, FFVII, FX at age 12 to 48 months: decreased levels of protein C, FII, FV, FFVII, FX. Thrombotic events lead to short and long term complications for them. Although guidelines for thromboprophylaxsis and treatment are currently available, more researches are needed to increase the knowledge of how thrombosis develops and how to prevent its occurance. Our results suggest that FVL can be a predisposing molecular risk factor for thrombosis in these patients.